WHO’s new global guidance helps clinicians manage dengue, Zika, chikungunya, and yellow fever with protocols for fluids, symptom clues, and drug safety.
Arboviral diseases, once mostly found in tropical and subtropical regions, are now spreading worldwide. This growing spread is fueled by climate change, urbanization, population growth, and increased travel.
for the clinical management of four major arboviral infections: dengue, chikungunya, Zika virus, and yellow fever.mosquitoes, the primary vectors for these diseases, which significantly increases the risk for outbreaks in regions where such infections were previously uncommon. Designed to support clinicians, particularly in resource-limited settings, the guidelines provide evidence-based recommendations for diagnosing and managing these infections, where access to laboratory diagnostics and advanced care may be restricted. “The simultaneous circulation, frequency, and magnitude of outbreaks of these arboviruses are increasing globally, driven by the convergence of ecological, economic, and social factors, with consequent expansion of areas in which cases occur. This increasing incidence in endemic areas and the occurrence of imported and autochthonous disease cases in new areas require clinician awareness to recognize the disease and manage cases according to evidence-based guidance, a task complicated by the challenges in differentiating clinically between these infections, particularly in the early phases of illness,” the WHO guidance stated. The new guidelines are based on a thorough systematic review and follow the 2022 handbook developed by the, based in Washington, DC, the regional office of the WHO for the Americas. While the 2022 handbook focused on arboviral disease management in the Americas, a group of international experts revised and expanded the guidelines to address global needs. One of the key challenges highlighted in the new WHO guidelines is the difficulty in distinguishing between arboviral infections in regions where multiple arboviruses may circulate simultaneously, making clinical differentiation challenging, particularly where diagnostic testing is not readily available. Because early symptoms often overlap, WHO guidelines emphasize the need for laboratory confirmation while also providing clinical features to help differentiate between arboviral infections during the initial diagnosis. Dengue, the most prevalent arboviral infection, is typically marked by thrombocytopenia , progressive increase in hematocrit, and leukopenia. These are key clinical indicators of disease severity. In chikungunya, persistent arthralgia is the most prominent distinguishing feature. Pruritus is more commonly observed in Zika infections. The WHO guidelines present comprehensive recommendations for treating these diseases based on disease severity, dividing cases into nonsevere and severe. For patients with suspected or confirmed nonsevere dengue, chikungunya, Zika, or yellow fever, the WHO recommends oral rehydration using small and frequent sips throughout the day. Paracetamol or dipyrone is advised for managing pain and fever.Nonsteroidal anti-inflammatory drugs should be avoided regardless of disease severity. For hospitalized patients with suspected or confirmed severe arboviral disease, the WHO provides detailed clinical guidance, including.Monitor IV fluid management using capillary refill time.Use a passive leg raise test in patients in shock when the clinician is unsure about the need to administer more IV fluids.Avoid prophylactic platelet transfusions in patients with platelet counts< 50,000/μL unless active bleeding.
Tropical Disease ZIKV Zika Zika Disease Zika Fever Zika Virus Zika Virus (ZIKV) Dengue Dengue Fever Clinical Guidelines Guidelines Yellow Fever Yellow Jack Black Vomit Vomito Negro Fever Pyrexia Febrile Response Platelet Count Thrombocyte Count Platelets Thrombocytes Platelet Count (PLT) Pain Management Arthralgia Painful Joint Joint Pain
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
RFK Jr. says U.S. will stop funding global vaccine group over 'vaccine safety' issuesThe secretary of health and human services said that funding will be curtailed until Gavi, the Vaccine Alliance, takes into account the science of vaccine safety in its campaigns.
Read more »
RFK Jr. says U.S. will stop funding global vaccine group over 'vaccine safety' issuesThe secretary of health and human services said that funding will be curtailed until Gavi, the Vaccine Alliance, takes into account the science of vaccine safety in its campaigns.
Read more »
Iran's Khamenei Issues First Statement Since Israel War EndedThe Iranian Supreme Leader is addressing the nation as Trump's fragile ceasefire holds up.
Read more »
Iran’s top cleric issues global ‘fatwa’ call to violence against Trump and NetanyahuPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
Former Raptors Exec Masai Ujiri Issues First Public Comments Since FiringUjiri had one year left on his contract with the franchise, which he had been with since 2013.
Read more »
Nuclear winter could decimate 87% of global corn, trigger catastrophic global famine: StudyThe team modeled how various nuclear winter scenarios could impact global production of corn, which is one of the most widely planted grain crops around the globe.
Read more »